Zimbabwe has declined a significant American health deal worth $367m (£272m) over five years due to Washington's insistence on confidential biological samples.
This rejection came to light after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesperson later stated that the United States was requesting biological samples for scientific study and commercial purposes while was unwilling to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more talks to secure a deal acceptable to all parties so the country's critical HIV treatment initiative can continue.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a similar deal with the US after concerns were raised about the security of citizens' health data.
After returning to office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to boost transparency and accountability.
As per reports, Sixteen nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our population should a future health crisis arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures previously established through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We welcome further discussions with our American counterparts on how future collaboration could be structured in a way that respects the independence and dignity of each country."
Medical Community Reaction
A leading public health body said it recognised the government's concerns, but recommended that negotiations should continue given that a large portion of the nation's HIV programmes depended on international support.
"If technical issues arise, such as those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it said.
The situation highlights the complex tensions between accepting vital foreign assistance and safeguarding a country's data in an increasingly data-driven world.